BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head Survey

Korro Bio (NASDAQ:KRRO) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Korro Bio and BioLineRx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39 million	20.37	-$117.26 million	($10.00)	-0.88
BioLineRx	$1.18 million	8.76	-$1.17 million	($1.69)	-1.23

BioLineRx has lower revenue, but higher earnings than Korro Bio. BioLineRx is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Korro Bio and BioLineRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
BioLineRx	-502.08%	-34.80%	-18.27%

Volatility and Risk

Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Korro Bio and BioLineRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
BioLineRx	1	0	0	0	1.00

Korro Bio presently has a consensus price target of $16.50, indicating a potential upside of 86.76%. Given Korro Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than BioLineRx.

Institutional and Insider Ownership

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Korro Bio beats BioLineRx on 11 of the 15 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.